FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to soluble recombinant fused protein having the ability to bind acetylcholinesterase inhibitors. Disclosed is a recombinant fusion protein containing a polyhistidine sequence, a sequence of maltose-binding protein (MBP) of E. coli, a linker and a modified sequence of human BCE. Also presented is a genetic construct coding the declared fusion protein, a plasmid expression vector and a producer protein of the fused protein. Group of inventions enables to obtain a soluble fused protein with output of 5 mg per 1 g of wet biomass of bacterial culture and with elimination half-life from blood flow is 22.4 hours.
EFFECT: fused protein can be used as an antidote against various cholinesterase inhibitors.
4 cl, 7 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEOTIDE SEQUENCE ENCODING β-N-ACETYLHEXOZAAMINIDASE AGGREGATIBACTER ACTINOMYCETEMCOMITANS AND GENETIC STRUCTURES CONTAINING IT | 2021 |
|
RU2789544C1 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
| INCREASING METHOD OF PHOTOSYNTHETIC CARBON FIXATION WITH USE OF FUSION PROTEIN FROM MANY SUBUNITS OF GLICOLATE DEHYDROGENASE | 2011 |
|
RU2651501C2 |
| COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF LACTATE FROM C1-COMPOUNDS USING TRANSFORMANTS OF LACTATE DEHYDROGENASE | 2014 |
|
RU2710714C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| CHO-SE-9/4 CELL STRAIN, PRODUCER OF CHIMERIC HUMAN ERYTHROPOIETIN ANTIBODY AND CHIMERIC ANTIBODY PRODUCED BY SAID STRAIN | 2019 |
|
RU2717038C1 |
| BIOSENSOR SYSTEM FOR FAST DETECTION OF DETERMINED COMPONENTS | 2016 |
|
RU2717658C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
